Why Atai Life Sciences Stock Was So Lively This Week

Atai Life Sciences (NASDAQ: ATAI), a biotech focused on developing psychedelic-based medicines to treat mental health disorders, was a standout stock over the past few days in its rather limited peer group.That's because news of a top regulator's move on one of its developmental drugs was pushing the company's stock up by nearly 8% week to date as of early Friday morning, according to data compiled by S&P Global Market Intelligence. On Thursday, Atai announced that it and its clinical partner Beckley Psytech had received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for their investigational treatment BPL-003. This is a nasal spray that targets treatment-resistant depression (TRD) in adult patients.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool